Commitments and Contingencies - Contingent Consideration (Details) - USD ($) $ in Thousands |
3 Months Ended | |||
|---|---|---|---|---|
Mar. 31, 2023 |
Mar. 29, 2023 |
Dec. 31, 2022 |
Feb. 25, 2019 |
|
| Commitments And Contingencies | ||||
| Contingent consideration under RPAs and CPPAs | $ 125 | $ 75 | ||
| Aronora, Kuros, Affitech, ObsEva, and Merck KGaA | ||||
| Commitments And Contingencies | ||||
| Contingent consideration under RPAs and CPPAs | 0 | |||
| Royalty Purchase Agreement | Bioasis | ||||
| Commitments And Contingencies | ||||
| Contingent consideration under RPAs and CPPAs | 75 | $ 75 | ||
| Changes in estimated fair value of contingent consideration | 0 | |||
| Commercial Payment Purchase Agreement | Aptevo | ||||
| Commitments And Contingencies | ||||
| Contingent consideration under RPAs and CPPAs | $ 50 | |||
| Changes in estimated fair value of contingent consideration | $ 0 |
| X | ||||||||||
- Definition Changes in estimated fair value of contingent consideration. No definition available.
|
| X | ||||||||||
- Definition Commitments and contingencies. No definition available.
|
| X | ||||||||||
- Definition Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements, commercial payment purchase agreements and payment interest purchase agreements. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|